Fund moves
91.1%Stake
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
TVGN · NASDAQ · Biological Products, (No Diagnostic Substances)
Tevogen (TVGN) · oqro.io/stocks/TVGN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$5.90−0.40 (−6.35%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Tevogen was filed in the last 90 days. The latest on record was on Jun 12, 2024.
Since 2021, Tevogen insiders reported 3 open-market purchases and 15 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2024.
No open-market sale by an insider of Tevogen (TVGN) was filed with the SEC in the last 90 days.
No trade in Tevogen (TVGN) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−71.4% (−$14.76) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $20.67 on Nov 20, 2025 to $5.90 on Nov 20, 2026 (−71.4%). Disclosed in this range: 0 insider trades, 3 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Warren, Nj.
Last 12 months
−71.5%
Market value
$38.4M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 55K shares sold short (0.8% of shares outstanding), −1.0% vs the previous count, 4.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Fund moves
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Neal Flomenberg (See Remarks) sold ~$3.3K of Tevogen
Automatic saleNeal Flomenberg (See Remarks) sold ~$3.2K of Tevogen
Automatic saleInsider selling
Traded Jun 9, 2025 · filed the same dayNot reported under a pre-arranged trading plan
The CEO of Tevogen sold $1.77M of Tevogen shares. The filing does not indicate a pre-arranged trading plan.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Tevogen reported 3 open-market purchases and 15 sales since 2021; purchases in 2 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $6.6K3×3 trades |
| 2025 | — | $2.5M8×8 trades |
| 2024 | $4.5K2×2 trades | $1.75M1×1 trade |
| 2023 | — | $33.8M3×3 trades |
| 2021 | —1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 18, 2025, TVGN is down 71.2% and the index fund is up 4.5%: 76 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much TVGN moves
Beta 1.5 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Notice of delisting or failure to meet listing rules
1 insider sold ~$6.6K in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $145K, at Sep 30, 2026
Net income, last 12 months
−$22.9M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Apr 26, 2024.
Who holds it
Things to keep in mind
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 9,000 words.
We are a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ CTLs, to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders, with the aim of addressing the significant unmet needs of large patient populations. We believe the full potential of T cell therapies remains largely untapped, and aspire to be the first biotechnology company offering commercially attractive, economically viable, and cost-effective personalized T cell therapies.
And 11 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 44.8% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (5.4% on ATS, 39.4% with other brokers), below its 26-week average of 47.2%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: SIGMA X2 (40.5%), UBS ATS (24.3%), INTELLIGENT CROSS LLC (13.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Latest annual report filed Mar 31, 2026, compared with the one filed Apr 2, 2025. Read the filing
From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of our business. We are not currently a party to any material pending legal proceedings.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.